At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02616 CSTONE PHARMA-B
Market Closed 03-28 16:08:10
3.380
-0.120
-3.43%
High3.640Low3.220Vol8.86M
Open3.450D1 Closing3.500Amplitude12.00%
Mkt Cap4.34BTradable Cap4.34BTotal Shares1.28B
T/O30.09MT/O Rate0.69%Tradable Shares1.28B
P/B8.67ROE-26.57%EPS-0.31
52wk High3.89052wk Low0.800P/E-10.86
Dividend0.00Div.Yield0.00ROA-13.91%
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
BRIEF-CStone Pharmaceuticals Announces 2024 Annual Results And Recent Business Progress
Reuters  ·  03-27 12:39
BRIEF-CStone Pharmaceuticals Announces 2024 Annual Results And Recent Business Progress
CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress
THOMSON REUTERS  ·  03-27 11:55
CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress
Press Release: CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress
Dow Jones  ·  03-27 11:55
Press Release: CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress
CStone Pharmaceuticals - Revenue Was RMB407.2 Mln for Year
THOMSON REUTERS  ·  03-27 08:32
CStone Pharmaceuticals - Revenue Was RMB407.2 Mln for Year
CStone Seeks EU Approval for New Indication of Lung Cancer Drug
MT Newswires Live  ·  03-24
CStone Seeks EU Approval for New Indication of Lung Cancer Drug
CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage Iii Non-Small Cell Lung Cancer
THOMSON REUTERS  ·  03-24
CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage Iii Non-Small Cell Lung Cancer
CStone Pharmaceuticals Leads Our Top 3 Global Penny Stock Picks
Simply Wall St.  ·  03-19
CStone Pharmaceuticals Leads Our Top 3 Global Penny Stock Picks
CStone Pharmaceuticals Submit Clinical Trial Application in Australia for Cancer Drug
MT Newswires Live  ·  03-06
CStone Pharmaceuticals Submit Clinical Trial Application in Australia for Cancer Drug
CStone Submits Clinical Trial Application in Australia for Cs5001 (Ror1 ADC) in Combination With First-Line Standard-of-Care for Dlbcl
THOMSON REUTERS  ·  03-06
CStone Submits Clinical Trial Application in Australia for Cs5001 (Ror1 ADC) in Combination With First-Line Standard-of-Care for Dlbcl
CStone Pharmaceuticals Carries Out First Dosing in Multi-Cancer Drug Trial
MT Newswires Live  ·  03-04
CStone Pharmaceuticals Carries Out First Dosing in Multi-Cancer Drug Trial
CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of Cs2009, a Pd-1/Vegf/Ctla-4 Trispecific Antibody
THOMSON REUTERS  ·  03-04
CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of Cs2009, a Pd-1/Vegf/Ctla-4 Trispecific Antibody
There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 28% Share Price Rise
Simply Wall St.  ·  02-14
There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 28% Share Price Rise
CStone Pharmaceuticals' Lung Cancer Drug Included in ESMO Living Guideline
MT Newswires Live  ·  02-10
CStone Pharmaceuticals' Lung Cancer Drug Included in ESMO Living Guideline
CStone Announces Inclusion of Cejemly® (Sugemalimab) as a First-Line Combination Therapy for Nsclc in Esmo Guideline
THOMSON REUTERS  ·  02-10
CStone Announces Inclusion of Cejemly® (Sugemalimab) as a First-Line Combination Therapy for Nsclc in Esmo Guideline
CStone Pharmaceuticals - Announces Inclusion of Sugemalimab (Cejemly®) as First-Line Combination Therapy for Nsclc
THOMSON REUTERS  ·  02-10
CStone Pharmaceuticals - Announces Inclusion of Sugemalimab (Cejemly®) as First-Line Combination Therapy for Nsclc
CStone Pharmaceuticals Partners Up with Latin American Pharmaceutical Firm
MT Newswires Live  ·  02-03
CStone Pharmaceuticals Partners Up with Latin American Pharmaceutical Firm
CStone Pharmaceuticals - CStone and Steincares Enter Into Partnership to Market Sugemalimab in Latin America
THOMSON REUTERS  ·  01-27
CStone Pharmaceuticals - CStone and Steincares Enter Into Partnership to Market Sugemalimab in Latin America
CStone Pharmaceuticals Submits Application for Solid Tumor Drug Trials in Australia
MT Newswires Live  ·  2024-12-23
CStone Pharmaceuticals Submits Application for Solid Tumor Drug Trials in Australia
CStone Announces Submission of Clinical Trial Application in Australia for Cs2009, an Innovative Pd-1/Vegf/Ctla-4 Trispecific Antibody
THOMSON REUTERS  ·  2024-12-23
CStone Announces Submission of Clinical Trial Application in Australia for Cs2009, an Innovative Pd-1/Vegf/Ctla-4 Trispecific Antibody
CStone Pharmaceuticals Enrolls First Patient in Phase 1B Trial for Anti-Tumor Drug
MT Newswires Live  ·  2024-12-19
CStone Pharmaceuticals Enrolls First Patient in Phase 1B Trial for Anti-Tumor Drug

Introduction

Company Name.
CSTONE PHARMA-B
Affiliated Markets:
SEHK
Listing Date:
2019-02-25
Main Business:
CStone Pharmaceuticals is a China-based investment holding company. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The Company conducts its businesses mainly in domestic market.
Issue price:
12.000
Invest in Global Markets with Tiger Brokers!
Open App